These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38198667)

  • 1. Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field.
    Avgousti H; Feinstein MJ
    Top Antivir Med; 2023 Dec; 31(5):559-565. PubMed ID: 38198667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
    Grinspoon SK; Fitch KV; Overton ET; Fichtenbaum CJ; Zanni MV; Aberg JA; Malvestutto C; Lu MT; Currier JS; Sponseller CA; Waclawiw M; Alston-Smith B; Cooper-Arnold K; Klingman KL; Desvigne-Nickens P; Hoffmann U; Ribaudo HJ; Douglas PS;
    Am Heart J; 2019 Jun; 212():23-35. PubMed ID: 30928825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.
    Fitch KV; Fulda ES; Grinspoon SK
    Curr Opin HIV AIDS; 2022 Sep; 17(5):293-300. PubMed ID: 35938463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.
    Riestenberg RA; Furman A; Cowen A; Pawlowksi A; Schneider D; Lewis AA; Kelly S; Taiwo B; Achenbach C; Palella F; Stone NJ; Lloyd-Jones DM; Feinstein MJ
    Am Heart J; 2019 Mar; 209():79-87. PubMed ID: 30685678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Hoffmann U; Lu MT; Olalere D; Adami EC; Osborne MT; Ivanov A; Aluru JS; Lee S; Arifovic N; Overton ET; Fichtenbaum CJ; Aberg JA; Alston-Smith B; Klingman KL; Waclawiw M; Burdo TH; Williams KC; Zanni MV; Desvigne-Nickens P; Cooper-Arnold K; Fitch KV; Ribaudo H; Douglas PS; Grinspoon SK;
    Am Heart J; 2019 Jun; 212():1-12. PubMed ID: 30928823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.
    Nazari I; Feinstein MJ
    Clin Microbiol Rev; 2024 Mar; 37(1):e0009822. PubMed ID: 38299802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial.
    Gilbert JM; Fitch KV; Grinspoon SK
    Top Antivir Med; 2015; 23(4):146-9. PubMed ID: 26713505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired response of memory Treg to high density lipoproteins is associated with intermediate/high cardiovascular disease risk in persons with HIV.
    Atehortua L; Baig M; Morris J; Trentman S; Davidson WS; Fichtenbaum CJ; Chougnet CA
    Front Immunol; 2023; 14():1146624. PubMed ID: 36969259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.
    Mehraj V; Chen J; Routy JP
    Front Immunol; 2024; 15():1339338. PubMed ID: 38655259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.
    Looby SE; Kantor A; Burdo TH; Currier JS; Fichtenbaum CJ; Overton ET; Aberg JA; Malvestutto CD; Bloomfield GS; Erlandson KM; Cespedes M; Kallas EG; Masiá M; Thornton AC; Smith MD; Flynn JM; Kileel EM; Fulda E; Fitch KV; Lu MT; Douglas PS; Grinspoon SK; Ribaudo HJ; Zanni MV
    Clin Infect Dis; 2022 Oct; 75(8):1324-1333. PubMed ID: 35235653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Disease Risk Among Transgender People with HIV.
    Cetlin M; Fulda ES; Chu SM; Hamnvik OR; Poteat T; Zanni MV; Toribio M
    Curr HIV/AIDS Rep; 2021 Oct; 18(5):407-423. PubMed ID: 34626323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.
    Hoffmann U; Lu MT; Foldyna B; Zanni MV; Karady J; Taron J; Zhai BK; Burdo T; Fitch KV; Kileel EM; Williams K; Fichtenbaum CJ; Overton ET; Malvestutto C; Aberg J; Currier J; Sponseller CA; Melbourne K; Floris-Moore M; Van Dam C; Keefer MC; Koletar SL; Douglas PS; Ribaudo H; Mayrhofer T; Grinspoon SK;
    JAMA Netw Open; 2021 Jun; 4(6):e2114923. PubMed ID: 34185068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
    Grinspoon SK; Douglas PS; Hoffmann U; Ribaudo HJ
    J Infect Dis; 2020 Jul; 222(Suppl 1):S1-S7. PubMed ID: 32645161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease.
    Gallegos Aragon K; Ray G; Conklin J; Stever E; Marquez C; Magallanes A; Anderson J; Jakeman B
    Am J Health Syst Pharm; 2022 Nov; 79(22):2026-2031. PubMed ID: 35976174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.
    Gillis J; Smieja M; Cescon A; Rourke SB; Burchell AN; Cooper C; Raboud JM;
    Antivir Ther; 2014; 19(3):309-17. PubMed ID: 24429380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk of atherosclerotic cardiovascular disease in people with hemophilia: the importance of primary prevention.
    Dix C; Dolan G; Hunt BJ
    J Thromb Haemost; 2024 May; 22(5):1304-1312. PubMed ID: 38309435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of coronary inflammation in antiretroviral treated people with HIV infection and active HIV/hepatitis C virus co-infection.
    Jeudy J; Patel P; George N; Burrowes S; Husson J; Chua J; Conn L; Weiss RG; Bagchi S
    AIDS; 2022 Mar; 36(3):399-407. PubMed ID: 34750294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.
    deFilippi C; Toribio M; Wong LP; Sadreyev R; Grundberg I; Fitch KV; Zanni MV; Lo J; Sponseller CA; Sprecher E; Rashidi N; Thompson MA; Cagliero D; Aberg JA; Braun LR; Stanley TL; Lee H; Grinspoon SK
    J Infect Dis; 2020 Aug; 222(6):929-939. PubMed ID: 32310273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection.
    Lang R; Humes E; Hogan B; Lee J; D'Agostino R; Massaro J; Kim A; Meigs JB; Borowsky L; He W; Lyass A; Cheng D; Kim HN; Klein MB; Cachay ER; Bosch RJ; Gill MJ; Silverberg MJ; Thorne JE; McGinnis K; Horberg MA; Sterling TR; Triant VA; Althoff KN
    J Am Heart Assoc; 2022 Oct; 11(19):e026473. PubMed ID: 36129038
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.